Scarica l'app Stockscreener
1.33
6.40%
0.08
Pre-mercato:
1.33
Precedente Chiudi:
$1.25
Aprire:
$1.27
Volume 24 ore:
264.41K
Relative Volume:
0.45
Capitalizzazione di mercato:
$70.93M
Reddito:
-
Utile/perdita netta:
$-77.74M
Rapporto P/E:
-0.8991
EPS:
-1.4793
Flusso di cassa netto:
$-73.61M
1 W Prestazione:
-0.75%
1M Prestazione:
-18.40%
6M Prestazione:
-4.32%
1 anno Prestazione:
+40.86%
Intervallo 1D:
$1.25
$1.335
Intervallo di 1 settimana:
$1.25
$1.35
Portata 52W:
$0.81
$1.88
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Nome
Pmv Pharmaceuticals Inc
Settore
Industria
Telefono
(609) 642-6670
Indirizzo
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.33 | 66.66M | 0 | -77.74M | -73.61M | -1.4793 |
VRTX
Vertex Pharmaceuticals Inc
|
446.78 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.85 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.50 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.28 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.42 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-05-13 | Iniziato | Craig Hallum | Buy |
| 2024-04-12 | Iniziato | Jefferies | Buy |
| 2023-12-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-19 | Iniziato | Oppenheimer | Perform |
| 2021-08-02 | Iniziato | Guggenheim | Buy |
| 2021-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Cowen | Outperform |
| 2020-10-20 | Iniziato | Evercore ISI | Outperform |
| 2020-10-20 | Iniziato | Goldman | Neutral |
Mostra tutto
Pmv Pharmaceuticals Inc Borsa (PMVP) Ultime notizie
GUTS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Energy Moves: Will PMV Pharmaceuticals Inc outperform its industry peers2026 Momentum & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Dividend Watch: Is PMV Pharmaceuticals Inc exposed to currency risksQuarterly Earnings Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Quarterly Recap: Is Edgewell Personal Care Company forming bullish engulfing patternsIPO Watch & Growth Focused Entry Reports - baoquankhu1.vn
PLRX PE Ratio & Valuation, Is PLRX Overvalued - Intellectia AI
Cantargia AB (7V3.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Large Growth in Short Interest - MarketBeat
Aug Closing: Is PMV Pharmaceuticals Inc exposed to currency risks2026 Market Sentiment & Target Return Focused Stock Picks - baoquankhu1.vn
Why EXEL stock attracts strong analyst attention - baoquankhu1.vn
Analyst Upgrade: Is PMV Pharmaceuticals Inc benefiting from interest rate changesInflation Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Complete List of HealthcareBiotechnologyBiotechnology Stocks - GuruFocus
PMV Pharmaceuticals Insider Sellers Vindicated After 11% Drop - simplywall.st
Aug Swings: Is PMV Pharmaceuticals Inc exposed to currency risksDip Buying & Low Volatility Stock Recommendations - baoquankhu1.vn
US Market Wrap: Is PMV Pharmaceuticals Inc a potential multi bagger2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update - MarketBeat
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology - TipRanks
PMV Pharmaceuticals (PMVP) CFO receives 240,000-share stock option grant - Stock Titan
COO at PMV Pharmaceuticals (NASDAQ: PMVP) awarded 319,270 options - Stock Titan
PMV Pharmaceuticals (PMVP) awards 303,310 stock options to Chief Development Officer - Stock Titan
PMV Pharmaceuticals (PMVP) awards CEO 744,960 employee stock options - Stock Titan
PMV Pharmaceuticals (NASDAQ:PMVP) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Trend Recap: Does TriNet Group Inc have pricing powerEarnings Overview Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
PMV Pharmaceuticals, Inc.Common Stock (NQ: PMVP - The Chronicle-Journal
Risk On: Whats the outlook for PMV Pharmaceuticals Incs sectorWeekly Trend Report & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PMVP Reports Positive Phase 2 Results, Eyes 2027 NDA Submission - GuruFocus
PMV Pharma (PMVP) Reports Decline in Cash Reserves by Year-End 2 - GuruFocus
PMV Pharmaceuticals Reports Progress in PYNNACLE Trial of Rezatapopt for Ovarian Cancer and Announces Orphan Drug Designation from FDA - Quiver Quantitative
PMV Pharmaceuticals 10-K: Revenue $0, EPS $(1.48) — FY2025 results - TradingView
PMVP: Net loss widened to $77.7M as rezatapopt advanced in trials; cash runway extends to Q2 2027 - TradingView
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights - Yahoo Finance
OrbiMed exits PMV Pharmaceuticals (PMVP) after selling 4.98M shares at $1.62 - Stock Titan
PMVP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
PMVP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PMV Pharmaceuticals Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Health Rounds: Researchers find cellular clues to explain faster pain recovery in men - marketscreener.com
PMV Pharma’s rezatapopt study published in New England Journal - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
PMV Pharmaceuticals (PMVP) Publishes Positive Phase 1 Results fo - GuruFocus
PMV Pharma’s rezatapopt study published in New England Journal By Investing.com - Investing.com UK
New England Journal of Medicine Publishes First-in-Human - GlobeNewswire
Risk Analysis: Is PMV Pharmaceuticals Inc benefiting from interest rate changes2025 Biggest Moves & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
PMV Pharmaceuticals (PMVP) to Release Quarterly Earnings on Monday - Defense World
Avadel Pharmaceuticals (AVDL) to Release Earnings on Monday - Defense World
Decliners Report: Can NSYS lead its sector in growthTrade Exit Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Signal Recap: How much upside does LNKB haveJuly 2025 PostEarnings & Verified Swing Trading Watchlists - baoquankhu1.vn
Dow Update: Is Oxbridge Re Holdings Limited benefiting from interest rate changes2025 Geopolitical Influence & Short-Term High Return Ideas - baoquankhu1.vn
Growth Review: Is Accretion Acquisition Corp Equity Right stock risky to hold nowMarket Activity Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Will PMV Pharmaceuticals Inc outperform its industry peersJuly 2025 WrapUp & Weekly Market Pulse Alerts - baoquankhu1.vn
PMV Pharmaceuticals (NASDAQ:PMVP) Trading Up 0.9%Time to Buy? - MarketBeat
Fund Flows: Whats the RSI of PMV Pharmaceuticals Inc stockMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
Pmv Pharmaceuticals Inc Azioni (PMVP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pmv Pharmaceuticals Inc Azioni (PMVP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
1.57%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):